Navigation Links
Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008
Date:5/8/2008

Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding

High-Risk Plaques in Coronary Arteries

DOYLESTOWN, Pa., May 8 /PRNewswire/ --- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, will present new experimental results on the chemical characterization and treatment of rupture-prone or "vulnerable" plaques, with a focus on the vPredict(TM) Optical Catheter System and the vProtect(TM) Luminal Shield, at the upcoming EuroPCR 2008 conference to be held in Barcelona, Spain from May 13 to 16.

The vProtect Luminal Shield was designed by Prescient Medical to treat soft, atherosclerotic lesions that may be at risk of rupture or that have recently ruptured. The self-expanding design of vProtect is a departure from the balloon-expandable stents that are mainstays of current focal treatment for coronary artery disease (CAD). The vProtect Luminal Shield has been designed to limit complications commonly associated with the insertion of stents, including vessel injury, restenosis, neointimal hyperplasia, and thrombosis.

The presentations will be an integral part of a session entitled "Glimpse Into The Future: Current Understanding of High-Risk Atherosclerosis Coronary Lesions," which will be held on May 14, 2008 from 13:30 to 16:50 in Room 5 of the conference. Professor Patrick Serruys, head of the Erasmus Medical Center's Department of Interventional Cardiology, will co-chair the session, which features presentations from leading authorities on coronary artery disease, including Dr. Guillermo Tearney, a distinguished researcher on the development and validation of new optical diagnostic technologies at Massachusetts General Hospital; and Dr. Juan Granada, Medical Director at the Jack H. Skirball Center for Cardiovascular Research. Dr. Tearney will present results from Prescient's vPredict Optical Catheter System in his presentation, "Spectroscopy Imaging of Coronary Lesions: Compositional Assessment". Dr. Granada will reveal the latest results obtained with the vProtect Luminal Shield in "Shielding for High-Risk Plaque."

Prescient Medical is dedicated to providing interventional cardiologists with new methods for effectively addressing different plaque types through enhanced conformability and adaptability of the Shield device to vessel structure, morphology, and dynamic forces. According to Dr. Granada, vProtect represents a revolutionary departure from the use of rigid balloon-expandable stents for coronary artery disease: "The vProtect Luminal Shield is the first step toward the goal of creating products that will achieve plaque stabilization and promote vascular healing. Prescient Medical has designed this device to conform to the physiology of the coronary arteries, rather than force the arteries to conform to a rigid metal scaffold."

For more information on Prescient Medical or its products, as well as the presentations of Professor Serruys, Dr. Tearney, or Dr. Granada, please contact Ilana Odess, General Manager of Prescient Medical, at (917) 941-9990. Ms. Odess will be available to meet with representatives of the medical community throughout the conference at the Rafael Hoteles Diagonal Port, Estrellas, C/Lope de Vega, 4, 08005, 34-932-302 000- Suite Clave (201).

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at http://www.prescientmedical.com or call 866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
4. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
5. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
6. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
7. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
8. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
9. Tryton Medical, Inc. Closes $14 Million Financing
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology:
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):